Sex-associated molecular differences for cancer immunotherapy
Immunotherapy has tremendous potential to treat many patients with cancer. In this study, the authors investigate the impact of gender on the response to therapy, highlighting the importance to include omics profiling in clinical studies.
Guardado en:
Autores principales: | Youqiong Ye, Ying Jing, Liang Li, Gordon B. Mills, Lixia Diao, Hong Liu, Leng Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9229cc6794b14bf990f2e98b19713758 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Ying Jing, et al.
Publicado: (2020) -
Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer
por: Zhao Zhang, et al.
Publicado: (2019) -
DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder Cancer
por: Fangdie Ye, et al.
Publicado: (2021) -
Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer
por: Tiziana Vavalà, et al.
Publicado: (2021) -
Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
por: Chenlu Li, et al.
Publicado: (2021)